Skip to main content
Top
Published in: PharmacoEconomics 5/2012

01-05-2012 | Original Research Article

Changes in Antipsychotic Medication Use after Implementation of a Medicaid Mental Health Carve-Out in the US

Author: Dr John Robst

Published in: PharmacoEconomics | Issue 5/2012

Login to get access

Abstract

Background: Many Medicaid programmes now offer behavioural healthcare through managed care organizations. Medicaid programmes are concerned about carve-outs because the use of non-included services may rise, limiting the efficiencies anticipated with the implementation of managed care. There also exist concerns that patients with serious mental illness may receive reduced care through managed care and consequently have poorer outcomes.
Objective: This study examined prescription drug utilization among Medicaid recipients with the implementation of a mental health carve-out plan in Florida. In particular, this study examined short-run changes in the utilization of antipsychotic medications among individuals diagnosed with schizophrenia or episodic mood disorders with the implementation of Prepaid Mental Health Plans (PMHPs) in Florida Medicaid.
Methods: This study used Medicaid data from 38 counties in Florida that implemented the PMHP programme in 2005 and 2006. The sample was limited to individuals aged ≤64 years who were continuously enrolled in Medicaid. Individuals were required to have at least two diagnoses of schizophrenia, episodic mood disorders, delusional disorders or other nonorganic disorders (three-digit International Classification of Diseases, Ninth Revision [ICD-9] code of 295–298).
Five different outcome measures were examined on a monthly basis for the 6 months pre–and post–PMHP implementation: penetration; adherence; Medicaid expenditures for antipsychotics; polypharmacy (multiple antipsychotic medications); and whether dosing was within guidelines. Generalized estimating equations were used to estimate associations between individual and insurance characteristics, and the outcome variables. The analyses were conducted using SAS procedure GENMOD. Empirical (robust) standard errors were calculated to account for repeated observations on the same individual.
Results: There were 153 720 monthly observations for the 12 810 people in the sample. Seventy-four percent of the sample was aged between 21 and 54 years, while 65% were female, 30% White, 14% Black and 44% Hispanic. The large proportion of Hispanics stems from the introduction of the PMHP programme in Dade County (Miami).
The results indicate the implementation of the PMHP was associated with increased penetration, but reduced adherence, polypharmacy and expenditures by the Medicaid agency. There was no change in the likelihood of prescriptions being written within recommended dosage ranges.
Conclusion: The introduction of the PMHP was associated with short-run changes in medication utilization among individuals with serious mental illness.
Literature
1.
go back to reference Haslanger K, Tallon Jr J. Medicaid managed care: there’s more for states to do. Manag Care Q 2004; 12: 1–5PubMed Haslanger K, Tallon Jr J. Medicaid managed care: there’s more for states to do. Manag Care Q 2004; 12: 1–5PubMed
2.
go back to reference Holahan J, Rangarajan S, Schirmer M. Medicaid managed care payment rates in 1998. Health Aff 1999; 18: 217–27CrossRef Holahan J, Rangarajan S, Schirmer M. Medicaid managed care payment rates in 1998. Health Aff 1999; 18: 217–27CrossRef
3.
4.
go back to reference Tohen M, Vieta E. Antipsychotic agents in the treatment of bipolar mania. Bipolar Dis 2009; 11: 45–54CrossRef Tohen M, Vieta E. Antipsychotic agents in the treatment of bipolar mania. Bipolar Dis 2009; 11: 45–54CrossRef
5.
go back to reference Nelson JG, Papakostas GI. Atypical antipsychotic augmentation in major depressive disorder: a meta-analysis of placebo-controlled randomized trials. Am J Psychiatry 2009; 166: 980–91PubMedCrossRef Nelson JG, Papakostas GI. Atypical antipsychotic augmentation in major depressive disorder: a meta-analysis of placebo-controlled randomized trials. Am J Psychiatry 2009; 166: 980–91PubMedCrossRef
6.
go back to reference Gianfrancesco FD, Grogg AL, Mahmoud RA, et al. Differential effects of risperidone, olanzapine, clozapine, and conventional antipsychotics on type 2 diabetes: findings from a large healthplandatabase. J Clin Psychiatry 2002; 63: 920–30PubMedCrossRef Gianfrancesco FD, Grogg AL, Mahmoud RA, et al. Differential effects of risperidone, olanzapine, clozapine, and conventional antipsychotics on type 2 diabetes: findings from a large healthplandatabase. J Clin Psychiatry 2002; 63: 920–30PubMedCrossRef
7.
go back to reference Rosenheck RA. Open forum. Effectiveness versus efficacy of second-generation antipsychotics: haloperidol without anticholinergics as a comparator. Psychiatr Serv 2005; 56: 85–92 Rosenheck RA. Open forum. Effectiveness versus efficacy of second-generation antipsychotics: haloperidol without anticholinergics as a comparator. Psychiatr Serv 2005; 56: 85–92
8.
go back to reference Tandon R, Fleischhacker WW. Comparative efficacy of antipsychotics in the treatment of schizophrenia: a critical assessment. Schizophr Res 2005; 79: 145–55PubMedCrossRef Tandon R, Fleischhacker WW. Comparative efficacy of antipsychotics in the treatment of schizophrenia: a critical assessment. Schizophr Res 2005; 79: 145–55PubMedCrossRef
9.
go back to reference Patel N, Crismon L, Hoagwood K. Trends in the use of typical and atypical antipsychotics in children and adolescents. J Am Acad Child Adolesc Psychiatry 2005; 44: 548–56PubMedCrossRef Patel N, Crismon L, Hoagwood K. Trends in the use of typical and atypical antipsychotics in children and adolescents. J Am Acad Child Adolesc Psychiatry 2005; 44: 548–56PubMedCrossRef
10.
go back to reference Rascati KL, Johnsrud MT, Crismon ML, et al. Olanzapine versus risperidone in the treatment of schizophrenia: a comparison of costs among Texas Medicaid recipients. Pharmacoeconomics 2003; 21 (10): 683–97PubMedCrossRef Rascati KL, Johnsrud MT, Crismon ML, et al. Olanzapine versus risperidone in the treatment of schizophrenia: a comparison of costs among Texas Medicaid recipients. Pharmacoeconomics 2003; 21 (10): 683–97PubMedCrossRef
11.
go back to reference Eaddy M, Grogg A, Locklear J. Assessment of adherence with antipsychotic treatment and resource utilization in a Medicaid population. Clin Ther 2005; 27: 263–72PubMedCrossRef Eaddy M, Grogg A, Locklear J. Assessment of adherence with antipsychotic treatment and resource utilization in a Medicaid population. Clin Ther 2005; 27: 263–72PubMedCrossRef
12.
go back to reference Jones PB, Barnes TR, Davies L, et al. Randomized controlled trial of the effect on quality of life of second- vs firstgeneration antipsychotic drugs in schizophrenia: Cost Utility of the Latest Antipsychotic Drugs in Schizophrenia Study (CUtLASS 1). Arch Gen Psychiatry 2006; 63: 1079–87PubMedCrossRef Jones PB, Barnes TR, Davies L, et al. Randomized controlled trial of the effect on quality of life of second- vs firstgeneration antipsychotic drugs in schizophrenia: Cost Utility of the Latest Antipsychotic Drugs in Schizophrenia Study (CUtLASS 1). Arch Gen Psychiatry 2006; 63: 1079–87PubMedCrossRef
13.
go back to reference Thieda P, Beard S, Richter A, et al. An economic review of adherence with medication therapy in the treatment of schizophrenia. Psychiatr Serv 2003; 54: 508–16PubMedCrossRef Thieda P, Beard S, Richter A, et al. An economic review of adherence with medication therapy in the treatment of schizophrenia. Psychiatr Serv 2003; 54: 508–16PubMedCrossRef
14.
go back to reference Weiden PJ, Kozma C, Grogg A, et al. Partial adherence and risk of rehospitalization among California Medicaid patients with schizophrenia. Psychiatr Serv 2004; 55: 886–91PubMedCrossRef Weiden PJ, Kozma C, Grogg A, et al. Partial adherence and risk of rehospitalization among California Medicaid patients with schizophrenia. Psychiatr Serv 2004; 55: 886–91PubMedCrossRef
15.
go back to reference Dolder CR, Lacro JP, Dunn LB, et al. Antipsychotic medication adherence: is there a difference between typical and atypical agents? Am J Psychiatry 2002; 159: 103–8PubMedCrossRef Dolder CR, Lacro JP, Dunn LB, et al. Antipsychotic medication adherence: is there a difference between typical and atypical agents? Am J Psychiatry 2002; 159: 103–8PubMedCrossRef
16.
go back to reference Lacro JP, Dunn LB, Dolder CR, et al. Prevalence of and risk factors for medication nonadherence in patients with schizophrenia: a comprehensive review of recent literature. J Clin Psychiatry 2002; 63: 892–909PubMedCrossRef Lacro JP, Dunn LB, Dolder CR, et al. Prevalence of and risk factors for medication nonadherence in patients with schizophrenia: a comprehensive review of recent literature. J Clin Psychiatry 2002; 63: 892–909PubMedCrossRef
17.
18.
go back to reference Wallace NT, Bloom JR, Hu TW, et al. Medication treatment patterns for adults with schizophrenia in Medicaid managed care in Colorado. Psychiatr Serv 2005; 56: 1402–8PubMedCrossRef Wallace NT, Bloom JR, Hu TW, et al. Medication treatment patterns for adults with schizophrenia in Medicaid managed care in Colorado. Psychiatr Serv 2005; 56: 1402–8PubMedCrossRef
19.
go back to reference Azocar F, Cuffel BD, Goldman W, et al. Dissemination of guidelines for the treatment of major depression in a managed behavioral health care network. Psychiatr Serv 2001; 52 (8): 1014–6PubMedCrossRef Azocar F, Cuffel BD, Goldman W, et al. Dissemination of guidelines for the treatment of major depression in a managed behavioral health care network. Psychiatr Serv 2001; 52 (8): 1014–6PubMedCrossRef
20.
go back to reference Dickey B, Normand ST, Hermann RC, et al. Guideline recommendations for treatment of schizophrenia. Arch Gen Psychiatry 2003; 60: 340–8PubMedCrossRef Dickey B, Normand ST, Hermann RC, et al. Guideline recommendations for treatment of schizophrenia. Arch Gen Psychiatry 2003; 60: 340–8PubMedCrossRef
21.
go back to reference Ray WA, Daugherty JR, Meador KG. Effect of a mental health “carve-out” program on the continuity of antipsychotic therapy. N Engl J Med 2003; 348: 1885–94PubMedCrossRef Ray WA, Daugherty JR, Meador KG. Effect of a mental health “carve-out” program on the continuity of antipsychotic therapy. N Engl J Med 2003; 348: 1885–94PubMedCrossRef
22.
go back to reference Popkin MK, Lurie N, Manning W, et al. Changes in the process of care for Medicaid patients with schizophrenia in Utah’s prepaid mental health plan. Psychiatr Serv 1998; 49: 518–23PubMed Popkin MK, Lurie N, Manning W, et al. Changes in the process of care for Medicaid patients with schizophrenia in Utah’s prepaid mental health plan. Psychiatr Serv 1998; 49: 518–23PubMed
23.
go back to reference Ridgely S, Giard J, Shern D. Florida’s Medicaid mental health carve-out. J Behav Health Serv Res 1999; 26: 400–15PubMedCrossRef Ridgely S, Giard J, Shern D. Florida’s Medicaid mental health carve-out. J Behav Health Serv Res 1999; 26: 400–15PubMedCrossRef
24.
go back to reference Constantine RJ, Murrin MR, Dhont K, et al. Developing and testing new methods for the administrative data component of the managed behavioral health care evaluation in Florida. Tampa (FL): University of South Florida, 2006 Constantine RJ, Murrin MR, Dhont K, et al. Developing and testing new methods for the administrative data component of the managed behavioral health care evaluation in Florida. Tampa (FL): University of South Florida, 2006
25.
go back to reference Soumerai S, Zhang F, Ross-Degnan D, et al. Use of atypical drugs for schizophrenia in Maine following a policy change. Health Aff 2008; 27: 185–95CrossRef Soumerai S, Zhang F, Ross-Degnan D, et al. Use of atypical drugs for schizophrenia in Maine following a policy change. Health Aff 2008; 27: 185–95CrossRef
26.
go back to reference Valenstein M, Copeland LA, McCarthy JF, et al. Poor antipsychotic adherence among patients with schizophrenia: medication and patient factors. Schizophr Bull 2004; 30: 255–64PubMedCrossRef Valenstein M, Copeland LA, McCarthy JF, et al. Poor antipsychotic adherence among patients with schizophrenia: medication and patient factors. Schizophr Bull 2004; 30: 255–64PubMedCrossRef
27.
go back to reference Gilmer TP, Dolder CR, Folsom DP, et al. Antipsychotic polypharmacy trends among Medi-Cal beneficiaries with schizophrenia in San Diego County, 1999-2004. Psychiatr Serv 2007; 58: 1007–10PubMedCrossRef Gilmer TP, Dolder CR, Folsom DP, et al. Antipsychotic polypharmacy trends among Medi-Cal beneficiaries with schizophrenia in San Diego County, 1999-2004. Psychiatr Serv 2007; 58: 1007–10PubMedCrossRef
28.
go back to reference Lehman AF, Kreyenbuhl J, Buchanan RW, et al. The Schizophrenia Patient Outcomes Research Team (PORT): updated treatment recommendations, 2003. Schizophr Bull 2004; 30: 193–217PubMedCrossRef Lehman AF, Kreyenbuhl J, Buchanan RW, et al. The Schizophrenia Patient Outcomes Research Team (PORT): updated treatment recommendations, 2003. Schizophr Bull 2004; 30: 193–217PubMedCrossRef
29.
go back to reference Hardin J, Hilbe J. Generalized estimating equations. Danvers (MA): CRC Press, 2002CrossRef Hardin J, Hilbe J. Generalized estimating equations. Danvers (MA): CRC Press, 2002CrossRef
Metadata
Title
Changes in Antipsychotic Medication Use after Implementation of a Medicaid Mental Health Carve-Out in the US
Author
Dr John Robst
Publication date
01-05-2012
Publisher
Springer International Publishing
Published in
PharmacoEconomics / Issue 5/2012
Print ISSN: 1170-7690
Electronic ISSN: 1179-2027
DOI
https://doi.org/10.2165/11539830-000000000-00000

Other articles of this Issue 5/2012

PharmacoEconomics 5/2012 Go to the issue

Correspondence

The Authors’ Reply